Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Study Phase : IND Enabling
Sponsor : ONL Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ONL1204 Ophthalmic Solution is a novel, first-in-class small peptide Fas inhibitor designed to protect key retinal cells, including photoreceptors, from cell death that occurs in a range of retinal diseases and conditions.
Product Name : ONL1204
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
December 07, 2022
Lead Product(s) : ONL1204
Therapeutic Area : Ophthalmology
Highest Development Status : IND Enabling
Sponsor : ONL Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Corticotropin
Therapeutic Area : Neurology
Study Phase : Approved FDF
Sponsor : Upsher-Smith Laboratories
Deal Size : Undisclosed
Deal Type : Partnership
Details : AmbioPharm will manufacture the active pharmaceutical ingredient exclusively for Upsher-Smith. A contract manufacturing organization will exclusively supply Upsher-Smith with the finished product for sale in the United States.
Product Name : Acthar
Product Type : Hormone
Upfront Cash : Undisclosed
July 08, 2020
Lead Product(s) : Corticotropin
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Sponsor : Upsher-Smith Laboratories
Deal Size : Undisclosed
Deal Type : Partnership